I have read the prescribing information and it addresses the adjacent case but not this one.
I want a method I can write down and repeat, not a rule of thumb.
I would rather over-engineer this than discover a problem later, within reason.
Concretely, what should I do, and how would I know afterwards whether I did it right?
It helps to be literal here: the titration schedule is a tolerability instrument, not an efficacy one. Nothing in the ladder is there to make the compound work better; every step exists to make the gastrointestinal adverse-event curve survivable.
The argument against splitting a weekly dose is arithmetic rather than ideological. Peak-to-trough ratio for a seven-day half-life compound dosed weekly is about two. Split it into twice-weekly and the ratio falls to roughly 1.4. That is a real reduction in fluctuation and a negligible one in absolute terms, and you have doubled the number of stopper piercings and the number of small-volume measurements, each of which carries its own error.
Escalating in response to a plateau is a specific and common error of reasoning. A plateau after four to six months is the expected trajectory in every trial in the class — the curve flattens because energy expenditure falls with mass, not because the receptor stopped working. A dose step may still be reasonable; "the loss stopped" is not by itself the reason.
The STEP programme escalated semaglutide over sixteen weeks in four-week steps to 2.4 mg weekly, and the trial-product estimand versus treatment-policy estimand distinction accounts for most of the difference between the figures quoted from those papers.
Escalate on tolerability, hold when it costs you, and do not confuse a flattening curve with a failing drug.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsThe steady-state arithmetic is worth doing once, because it explains most of what people find confusing about weekly dosing.
Holding at a step for longer than four weeks before escalating does appear to reduce cumulative gastrointestinal burden, which is unsurprising given that adverse events cluster in the one to two weeks after each increase. What it does not do is change where you end up, provided you get there.
Extending the interval and reducing the dose are not equivalent manoeuvres. Reducing the dose lowers the whole concentration-time curve proportionally. Extending the interval lowers the average but deepens the trough, and for a compound whose effect on appetite tracks concentration, a deep trough is felt.
SURMOUNT-4 is the withdrawal trial to read on the maintenance question: after an open-label lead-in, randomised withdrawal produced substantial regain in the placebo arm while continued treatment produced continued loss. It is the cleanest available answer to "what happens if I stop".
The caveat that matters: dose decisions on a licensed medicine belong with a prescriber, and dose decisions on research-use-only material belong to a category where nobody has any obligation to you at all.
If you take one thing from this: dose rate drives tolerability, dose level drives exposure, and they are separate levers.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.